Research Article
Investigation of the Role of Oxidative Stress and Factors Associated with Cardiac Allograft Vasculopathy in Patients after Heart Transplantation
Table 2
Baseline characteristics of the study population divided into CAV 1 vs. CAV 2/3 groups.
| | Parameter | Patients CAV 1,
| Patients CAV 2/3,
| |
| | Donor data | | | | | Age (years) | 31.00 (22.00-3700) | 35.00 (23.50-41.00) | 0.735 | | Male (%) | 51 (73.9) | 23 (82.1) | 0.506 | | Recipient data at the time of study inclusion | | | | | Age (years) | 62.00 (53.00-67.00) | 60.00 (55.5-67.50) | 0.820 | | Male (%) | 51 (73.9) | 23 (82.1) | 0.506 | | Hypertension (%) | 48 (69.6) | 22 (78.6) | 0.657 | | Type 2 DM (%) | 47 (68.1) | 16 (57.1) | 0.406 | | Hypercholesterolemia (%) | 52 (75.4) | 20 (71.4) | 0.001 | | BMI (kg/m2) | 27.00 (25.00-30.00) | 27.00 (24.5-30.0) | 0.940 | | Hemoglobin (mmol/L) | 8.40 (7.80-9.20) | 8.95 (7.95-9.45) | 0.366 | | Leukocyte count (×109/L) | 6.42 (5.55-7.56) | 6.30 (5.19-7.77) | 0.811 | | ESR (mm/h) | 22.00 (12.00-42.00) | 30.0 (10.50–46.00) | 0.574 | | hs-CRP (mg/dL) | 5.65 (4.50-6.90) | 6.48 (5.26-7.80) | 0.163 | | INR | 0.99 (0.95-1.05) | 0.99 (0.95-1.05) | 0.883 | | Fibrinogen (mg/dL) | 396.00 (339.00-469.00) | 398.5 (321.0-476.50) | 0.735 | | Creatinine (μmol/L) | 114.00 (99.00-145.00) | 122.50 (95.00-148.00) | 0.793 | | Bilirubin (μmol/L) | 10.30 (7.40-14.80) | 10.85 (6.75-12.75) | 0.491 | | Urea (mmol/L) | 9.20 (7.20-11.40) | 8.35 (6.75-12.75) | 0.486 | | Uric acid (μmol/L) | 413.00 (356.00–484.00) | 389 (318.50-467.00) | 0.320 | | Albumin (g/L) | 45.00 (43.00-47.00) | 43.00 (42.00-45.00) | 0.03 | | HbA1c (%) | 6.00 (5.50-6.40) | 6.10 (5.50-6.75) | 0.466 | | Sodium (mmol/L) | 141.00 (139.00-142.00) | 141.50 (140.00-142.00) | 0.410 | | AST (U/L) | 22.00 (18.00-26.00) | 24.00 (18.00-29.00) | 0.370 | | ALT (U/L) | 17.00 (15.00-26.00) | 22.50 (15.50-28.50) | 0.200 | | ALP (U/L) | 88.00 (71.00-109.00) | 95.00 (78.00-119.00) | 0.153 | | GGTP (U/L) | 42.00 (25.00-75.00) | 37.00 (25.50–68.50) | 0.741 | | Cholesterol (mmol/L) | 4.71 (3.91-5.75) | 5.00 (4.26-5.56) | 0.458 | | Triglyceride (mmol/L) | 1.45 (1.17-2.20) | 1.42 (1.04-1.96) | 0.458 | | LDL (mmol/L) | 2.52 (2.07-3.44) | 2.93 (2.20-3.58) | 0.496 | | HDL (mmol/L) | 1.34 (1.08-1.68) | 1.39 (1.06-1.63) | 0.524 | | TAC (mmol/L) | 0.99 (0.90-1.05) | 0.98 (0.91-1.10) | 0.856 | | TOS (μmol/L) | 5.32 (4.54-6.50) | 5.54 (4.48-6.65) | 0.889 | | OSI | 5.47 (4.64-6.63) | 5.43 (4.41-6.96) | 0.921 | | LVEF (%) | 55.00 (51.00-57.00) | 55.00 (52.50-58.00) | 0.498 | | M. mofetil+tacrolimus (%) | 49 (71) | 21 (75.0) | 0.742 | | M. mofetil %+cyclosporine (%) | 20 (29.0) | 7 (25.00) | 0.742 | | Statin (%) | 46 (66.7) | 17 (60.7) | 0.020 | | Antioxidant supplement (%) | 8 (11.6) | 5 (17.9) | 0.541 |
|
|
Abbreviations: see Table 1. |
